Enovis (DJO): FDA 510(k) clearances across all its applicant names
FDA lists 409 510(k) clearances, 3 PMA and 0 De Novo decisions across the 18 applicant names Caduvo groups under Enovis (DJO), first 1977, latest 2026. Median 510(k) review time across these names: 88 days. Since 2017 the median was 90 days, against 116 days for all cleared 510(k)s in the same product codes. Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 12 | 80 |
| 2013 | 9 | 130 |
| 2014 | 12 | 97 |
| 2015 | 9 | 150 |
| 2016 | 10 | 108 |
| 2017 | 12 | 93 |
| 2018 | 4 | 116 |
| 2019 | 10 | 140 |
| 2020 | 9 | 161 |
| 2021 | 7 | 65 |
| 2022 | 9 | 127 |
| 2023 | 8 | 68 |
| 2024 | 5 | 52 |
| 2025 | 11 | 83 |
| 2026 | 4 | 107 |
The 18 FDA applicant names in this group
| Applicant name | 510(k) clearances | PMA | De Novo | Years |
|---|---|---|---|---|
| Encore Orthopedics, Inc. | 85 | 0 | 0 | 1993–2004 |
| Encore Medical L.P. | 82 | 0 | 0 | 2002–2026 |
| Chattanooga Group, Inc. | 81 | 0 | 0 | 1980–2009 |
| Lima Corporate S.P.A. | 64 | 0 | 0 | 2011–2026 |
| Empi | 60 | 0 | 0 | 1977–2010 |
| Djo, LLC | 13 | 1 | 0 | 2009–2026 |
| Dj Orthopedics, LLC | 6 | 0 | 0 | 2001–2002 |
| Limacorporate | 4 | 0 | 0 | 2019–2025 |
| Encore Medical, L.P Dba Enovis | 3 | 0 | 0 | 2023–2024 |
| Compex Technologies, Inc. | 2 | 0 | 0 | 2005–2007 |
| Encore Medical Corporation | 2 | 0 | 0 | 2005–2005 |
| Djo Global | 1 | 1 | 0 | 2014–2014 |
| Djo Surgical | 1 | 1 | 0 | 2009–2009 |
| Encore Medical, L.P. Dba Djo Surgical | 1 | 0 | 0 | 2022–2022 |
| Encore Medical, LLC | 1 | 0 | 0 | 2023–2023 |
| Mathys Corp. | 1 | 0 | 0 | 1991–1991 |
| Mathys Corp. of North America | 1 | 0 | 0 | 1991–1991 |
| Mathys, Ltd. | 1 | 0 | 0 | 2010–2010 |
Review time against the same product codes
Since 2017, 510(k)s cleared under these names took a median 90 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 116 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| JWH | Prosthesis, Knee, Patellofemorotibial, Semi-Constrained, Cemented, Polymer/Metal/Polymer | 39 | 39 |
| LPH | Prosthesis, Hip, Semi-Constrained, Metal/Polymer, Porous Uncemented | 37 | 37 |
| PHX | Shoulder Prosthesis, Reverse Configuration | 31 | 31 |
| IPF | Stimulator, Muscle, Powered | 28 | 28 |
| GZJ | Stimulator, Nerve, Transcutaneous, For Pain Relief | 24 | 24 |
| KWS | Prosthesis, Shoulder, Semi-Constrained, Metal/Polymer Cemented | 21 | 21 |
| LZO | Prosthesis, Hip, Semi-Constrained, Metal/Ceramic/Polymer, Cemented Or Non-Porous, Uncemented | 16 | 16 |
| IMG | Stimulator, Ultrasound And Muscle, For Use In Applying Therapeutic Deep Heat | 13 | 13 |
| JDI | Prosthesis, Hip, Semi-Constrained, Metal/Polymer, Cemented | 13 | 13 |
| EGJ | Device, Iontophoresis, Other Uses | 11 | 11 |
Plus 71 more product codes.
Review panels
- Orthopedic (253)
- Physical Medicine (81)
- Neurology (46)
- Gastroenterology and Urology (10)
- Cardiovascular (5)
- Dental (3)
- General and Plastic Surgery (2)
- Ear, Nose and Throat (1)
Most recent Enovis (DJO) 510(k) clearances
| 510(k) | Device | Applicant name | Product code | Decision date | Review days |
|---|---|---|---|---|---|
| K263086 | AltiVate Reverse® Glenosphere with RAVN Technology | Encore Medical L.P. | PHX | 2026-10-02 | 30 |
| K262721 | Spinalogic Bone Growth Stimulator | Djo, LLC | LOF | 2026-09-29 | 60 |
| K252352 | SMR Shoulder System; PRIMA Glenoid System; PRIMA Humeral System | Lima Corporate S.P.A. | PHX | 2026-01-22 | 177 |
| K252567 | AltiVate Reverse® ADLC Glenosphere | Encore Medical L.P. | PHX | 2026-01-15 | 154 |
| K252974 | EMPOWR Knee | Encore Medical L.P. | JWH | 2025-12-19 | 93 |
| K251833 | EMPOWR Acetabular® Liner Extension | Encore Medical L.P. | LPH | 2025-11-12 | 149 |
| K251718 | ArTT Augments and Buttresses and Bone Screws | Lima Corporate S.P.A. | LPH | 2025-08-29 | 86 |
| K252141 | AltiVate Reverse® Glenoid | Encore Medical L.P. | PHX | 2025-08-05 | 28 |
| K251776 | EMPOWR Revision Knee (EMPOWR Revision VVC+, e+ Tibial Insert) | Encore Medical L.P. | JWH | 2025-07-08 | 28 |
| K243826 | SMR Reverse HP Shoulder System | Lima Corporate S.P.A. | PHX | 2025-07-03 | 203 |
399 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| P050050 | PMA | SCANDINAVIAN TOTAL ANKLE REPLACEMENT SYSTEM (S.T.A.R.ANKLE) | 2009-05-27 |
| N980003 | PMA | KERAMOS CERAMIC/CERAMIC TOTAL HIP SYSTEM | 2003-11-26 |
| P910066 | PMA | ORTHOLOGIC (TM)1000 BONE GROWTH STIMULATOR | 1994-03-04 |
Recalls
12 product recalls in 8 recall events under these names; 5 initiated in the last five years.
196 product recalls in 88 recall events filed under other recalling-firm names cite a 510(k) or PMA held under these applicant names; 52 initiated in the last five years. Most often: Encore Medical, Lp (70), Encore Medical, LP (59), Zimmer Inc. (32).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to the applicant names above by name only, so recalls filed under other names are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
ClinicalTrials.gov lists 22 device studies (2 active or recruiting) with an industry lead sponsor under the 2 sponsor names below. Most recent:
- NCT05537753: Encore PFO Closure Device - The PerFOrm Trial (Encore Medical Inc.; Recruiting, started 2023-07-12)
- NCT05101057: A Retrospective Study to Examine the Effect of CMF Stimulation on Primary ACDF Patients (Encore Medical, L.P.; Unknown, started 2021-11-15)
- NCT03711175: The Influence of Repairing the Sub-scapularis on Outcomes After Reverse Arthroplasty (Encore Medical, L.P.; Enrolling by invitation, started 2018-09-28)
- NCT02688855: CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures (Encore Medical, L.P.; Unknown, started 2017-01-23)
- NCT02720159: Early Feasibility Study of the Percutaneous Osseointegrated Prosthesis (POP) (Encore Medical, L.P.; Unknown, started 2015-12)
| Lead sponsor name on ClinicalTrials.gov | Device studies |
|---|---|
| Encore Medical, L.P. | 21 |
| Encore Medical Inc. | 1 |
Sponsor names are matched to the applicant names above by name, with punctuation and legal suffixes removed, plus sponsor names reviewed for this group. Studies listed under other sponsor names are not counted.
Parent company SEC filings
Enovis CORP (ENOV): EDGAR filings, CIK 1420800. The parent's SEC registrant is entered by hand for this group, not matched by name.
How this group is built
Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
Encore Medical (Encore Orthopedics, Chattanooga 2002, Empi 2004) acquired DJO in 2006; DJO Global became part of Colfax and then Enovis (2022). Mathys and LimaCorporate acquired 2024. Includes filings made before each acquisition.
Sources
Frequently asked questions
How many FDA 510(k) clearances are listed across Enovis (DJO)'s applicant names?
FDA lists 409 510(k) clearances, 3 PMA and 0 De Novo decisions across the 18 applicant names Caduvo groups under Enovis (DJO), first 1977, latest 2026. FDA records each applicant name separately; Caduvo adds up the names listed on this page.
Which FDA applicant names does Enovis (DJO) file under?
The names with the most 510(k) clearances in this group are Encore Orthopedics, Inc. (85); Encore Medical L.P. (82); Chattanooga Group, Inc. (81); Lima Corporate S.P.A. (64); Empi (60). The full list of 18 names is on this page.
How long does FDA take to clear Enovis (DJO) 510(k)s?
The median time from FDA receipt to decision across 510(k)s cleared under these names is 88 days. Since 2017 the median was 90 days, against 116 days for all cleared 510(k)s in the same product codes.
Does the Enovis (DJO) count include acquired companies?
Yes. A group includes filings an acquired business made under its own name, including before the acquisition. Businesses that were sold are left out, and names whose ownership is unclear are not included. FDA does not group applicants; the sources for each grouping are listed on this page.
How many device clinical trials does Enovis (DJO) sponsor?
ClinicalTrials.gov lists 22 device studies (2 active or recruiting) with an industry lead sponsor under 2 sponsor names Caduvo groups under Enovis (DJO). ClinicalTrials.gov names the sponsor on each study; Caduvo adds up the names listed on this page.
Next steps
- See all 409 Enovis (DJO) clearances with predicates and recalls
- Run predicate analysis for product code JWH, Enovis (DJO)'s most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this grouping or data. Data and corrections policy.
All parent companies · FDA device companies by applicant name · FDA product code lookup